License Agreements (Details Narrative) - USD ($) |
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
Oct. 06, 2021 |
Jun. 16, 2021 |
Oct. 06, 2020 |
Aug. 23, 2020 |
Aug. 19, 2020 |
Mar. 19, 2018 |
Dec. 31, 2021 |
|
| Price per share | $ 4.00 | ||||||
| Number of common stock issued during period, value | $ 9,875,550 | ||||||
| CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member] | |||||||
| Number of common stock issued during period | 298,615 | ||||||
| Number of common stock issued during period, value | $ 8,000,000 | ||||||
| Common stock shares issued and outstanding | 5,039,033 | ||||||
| CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member] | Promet [Member] | |||||||
| Business Acquisition, Share Price | $ 26.79 | ||||||
| License Agreement [Member] | Ocuphire Pharma Inc [Member] | |||||||
| Number of common stock issued during period | 44,689 | ||||||
| Cash paid under license agreement | $ 200,000 | ||||||
| Liabilities assumed | $ 66,583 | ||||||
| License Agreement [Member] | Yuhan Corporation [Member] | |||||||
| Number of common stock issued during period | 500,000 | ||||||
| Milestone payments, description | In addition, we must pay Yuhan one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based on any sub-license agreement we may enter into | ||||||
| Milestone payment description | specific diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24 months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial with a product within 48 months | ||||||
| License Agreement [Member] | Yuhan Affiliate [Member] | Underwritten Public Offering [Member] | October 2020 [Member] | |||||||
| Shares issued in connection with our 2020 offering | 750,000 | ||||||
| Proceeds from offering | $ 3,000,000 | ||||||
| License Agreement [Member] | Elion Oncology, Inc. [Member] | |||||||
| Number of common stock issued during period | 825,000 | ||||||
| Milestone payments, description | As additional consideration, we will pay Elion development and regulatory milestone payments (a portion of which are payable in shares of our common stock and a portion of which are payable in cash) upon the achievement of certain milestones, which include FDA or other regulatory approval and dosing a patient | ||||||
| Milestone payment description | specific diligence milestones that consist of: (i) dosing a first patient in a Phase 1B clinical trial with a product within 12 months; and (ii) dosing a first patient with a product in a Phase 2 or 3 clinical trial within 48 months. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and a 90-day opportunity to cure such breach (which is shortened to 15 days for a payment breach). | ||||||
| Conditions for grant of licence, description | The grant of license was conditioned on the following being satisfied by October 30, 2020: (i) our closing on an equity financing of at least $15 million in gross proceeds and (ii) successful up-listing to Nasdaq. | ||||||
| Payment for license grant | $ 100,000 | ||||||
| Common stock, lock-up description | Such shares are subject to a lock-up, with 50% of such shares released from such lock up after six months and the remaining 25% tranches to be released following 9 months and 12 months, respectively | ||||||
| Stock reserved for future issuance | 100,000 | ||||||
| Price per share | $ 4.00 | ||||||
| License Agreement [Member] | Elion Oncology, Inc. [Member] | First Milestone [Member] | |||||||
| Number of common stock issued during period | 100,000 | ||||||
| Performance of milestone conditions, description | As part of the Elion License Agreement, we have agreed to issue to Elion 100,000 shares of our common stock on each of the first and second anniversary dates of the Elion License Agreement | ||||||
| License Agreement [Member] | Aposense, Ltd. [Member] | |||||||
| Number of common stock issued during period | 625,000 | ||||||
| Milestone payments, description | As additional consideration, we will pay Aposense development and regulatory milestone payments (up to $3.0 million per milestone) upon the achievement of certain milestones, which primarily consist of having a drug indication approved by a regulatory authority in the United States or another country. In addition, we will pay Aposense one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any sales milestone payments or royalties we receive with Aposense based on any sub-license agreement we may enter into | ||||||
| Common stock, lock-up description | Such shares are subject to a lock-up, with 40% of such shares released from such lock up after six months and the remaining two 30% tranches to be released upon completion of the next two subsequent quarters | ||||||
| License Agreement [Member] | Aposense, Ltd. [Member] | Maximum [Member] | |||||||
| Development and regulatory milestone payments | $ 3,000,000.0 |